Cargando…

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch

There are limited data on the safety and efficacy of switching to secukinumab from cyclosporine A (CyA) in patients with psoriasis. The purpose of the present study was to assess the efficacy and safety of secukinumab for 16 weeks after direct switching from CyA in patients with moderate‐to‐severe p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohtsuki, Mamitaro, Morita, Akimichi, Igarashi, Atsuyuki, Imafuku, Shinichi, Tada, Yayoi, Fujita, Hiroyuki, Fujishige, Ayako, Yamaguchi, Masako, Teshima, Rie, Tani, Yumiko, Nakagawa, Hidemi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655923/ https://www.ncbi.nlm.nih.gov/pubmed/28543617 http://dx.doi.org/10.1111/1346-8138.13911

Ejemplares similares

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
por: Okubo, Yukari, et al.
Publicado: (2019)

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023)

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
por: Umezawa, Yoshinori, et al.
Publicado: (2021)

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022)

Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
por: Imafuku, Shinichi, et al.
Publicado: (2020)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open‐label phase 3 study
por: Morita, Akimichi, et al.
Publicado: (2018)

Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes
por: Yano, Chizuko, et al.
Publicado: (2015)

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2019)

Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
por: Terui, Tadashi, et al.
Publicado: (2023)

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Acute generalized pustular bacterid
por: Kamiya, Koji, et al.
Publicado: (2017)

Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Reactive nonsexually related acute genital ulcers
por: Ueda, Yoshitaka, et al.
Publicado: (2017)

Biologics for Psoriasis during the COVID-19 Pandemic
por: Kamiya, Koji, et al.
Publicado: (2021)

Diagnosis and Intervention in Early Psoriatic Arthritis
por: Hioki, Tomoyuki, et al.
Publicado: (2022)

Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy
por: Imafuku, Shinichi, et al.
Publicado: (2018)

Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018
por: Kamiya, Koji, et al.
Publicado: (2021)

Comparison of the efficacy of cyclosporine and leflunomide in treating inflammatory colorectal polyps in miniature dachshunds
por: TANI, Akiyoshi, et al.
Publicado: (2020)

Granuloma Annulare in the Setting of Secukinumab
por: Clark, Matthew L., et al.
Publicado: (2018)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Secukinumab on Refractory Lupus Nephritis
por: Costa, Rita, et al.
Publicado: (2021)

Secukinumab-Induced Lymphocytic Colitis
por: Gandu, Siva Santosh Kumar, et al.
Publicado: (2022)

Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study
por: Ohata, Chika, et al.
Publicado: (2023)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results
por: Takahashi, Kota, et al.
Publicado: (2013)

Two Cases of Inadequate Response to Remimazolam
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fhc1np565quim6bm9m607uliqc